Henrique D. Teixeira

3.5k total citations · 4 hit papers
56 papers, 2.2k citations indexed

About

Henrique D. Teixeira is a scholar working on Dermatology, Immunology and Allergy and Physiology. According to data from OpenAlex, Henrique D. Teixeira has authored 56 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Dermatology, 23 papers in Immunology and Allergy and 21 papers in Physiology. Recurrent topics in Henrique D. Teixeira's work include Dermatology and Skin Diseases (41 papers), Asthma and respiratory diseases (21 papers) and Allergic Rhinitis and Sensitization (19 papers). Henrique D. Teixeira is often cited by papers focused on Dermatology and Skin Diseases (41 papers), Asthma and respiratory diseases (21 papers) and Allergic Rhinitis and Sensitization (19 papers). Henrique D. Teixeira collaborates with scholars based in United States, Canada and Germany. Henrique D. Teixeira's co-authors include Alvina D. Chu, Yihua Gu, Jonathan I. Silverberg, John Liu, Barry Ladizinski, Eric L. Simpson, Emma Guttman‐Yassky, Kim Papp, Diamant Thaçi and Rogério Meneghini and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Biochemical Journal.

In The Last Decade

Henrique D. Teixeira

55 papers receiving 2.1k citations

Hit Papers

Once-daily upadacitinib versus placebo in adolescents and... 2019 2026 2021 2023 2021 2021 2019 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
    2021 350 citations Emma Guttman‐Yassky, Henrique D. Teixeira et al. profile →
  2. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis
    2021 305 citations Andrew Blauvelt, Henrique D. Teixeira et al. profile →
  3. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
    2019 255 citations Emma Guttman‐Yassky, Diamant Thaçi et al. Journal of Allergy and Clinical Immunology profile →
  4. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
    2021 250 citations Kristian Reich, Henrique D. Teixeira et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Henrique D. Teixeira United States 21 1.7k 853 534 492 442 56 2.2k
Anna M. Tallman United States 21 944 0.6× 533 0.6× 205 0.4× 501 1.0× 260 0.6× 66 1.4k
Ga‐Young Ban South Korea 21 172 0.1× 219 0.3× 266 0.5× 332 0.7× 602 1.4× 71 1.2k
Martin Raithel Germany 24 127 0.1× 438 0.5× 188 0.4× 607 1.2× 293 0.7× 126 1.7k
William H. Yang Canada 18 181 0.1× 465 0.5× 239 0.4× 149 0.3× 403 0.9× 69 1.1k
Alfonso Oriente Italy 16 215 0.1× 131 0.2× 219 0.4× 455 0.9× 225 0.5× 32 1.2k
M. Lorini Italy 21 170 0.1× 335 0.4× 748 1.4× 395 0.8× 458 1.0× 80 1.4k
R. E. Schopf Germany 17 284 0.2× 104 0.1× 251 0.5× 656 1.3× 150 0.3× 54 1.2k
Ayşen Karaduman Türkiye 18 317 0.2× 61 0.1× 136 0.3× 243 0.5× 169 0.4× 71 1.4k
Anne Black United Kingdom 22 214 0.1× 123 0.1× 719 1.3× 255 0.5× 105 0.2× 47 1.4k
Charlotte Jonsson Sweden 20 208 0.1× 91 0.1× 177 0.3× 308 0.6× 44 0.1× 39 1.0k

Countries citing papers authored by Henrique D. Teixeira

Since Specialization
Citations

This map shows the geographic impact of Henrique D. Teixeira's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henrique D. Teixeira with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henrique D. Teixeira more than expected).

Fields of papers citing papers by Henrique D. Teixeira

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henrique D. Teixeira. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henrique D. Teixeira. The network helps show where Henrique D. Teixeira may publish in the future.

Co-authorship network of co-authors of Henrique D. Teixeira

This figure shows the co-authorship network connecting the top 25 collaborators of Henrique D. Teixeira. A scholar is included among the top collaborators of Henrique D. Teixeira based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henrique D. Teixeira. Henrique D. Teixeira is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bunick, Christopher G., Alan D. Irvine, Jonathan I. Silverberg, et al.. (2025). Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years. Journal of the European Academy of Dermatology and Venereology.
3.
4.
Simpson, Eric L., Vimal H. Prajapati, Yael A. Leshem, et al.. (2024). Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2). Dermatology and Therapy. 14(5). 1127–1144. 3 indexed citations
5.
Qian, Yuli, Eliza M. Raymundo, Kristina Unnebrink, et al.. (2024). Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis. Clinical Therapeutics. 46(10). 733–741. 3 indexed citations
6.
Silverberg, Jonathan I., Marjolein de Bruin‐Weller, Brian Calimlim, et al.. (2023). Aggregate Response Benefit in Skin Clearance and Itch Reduction with Upadacitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis®. Dermatitis. 35(3). 266–274. 1 indexed citations
7.
Silverberg, Jonathan I., Christopher G. Bunick, Peter Lio, et al.. (2023). 427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies. British Journal of Dermatology. 188(Supplement_3). 1 indexed citations
8.
Lio, Peter, Lawrence F. Eichenfield, Danielle Marcoux, et al.. (2023). 413 Improvement in itch, symptoms and quality of life with upadacitinib through week 16 in adults and adolescents with atopic dermatitis: results from phase 3 studies (Measure Up 1, Measure Up 2 and AD Up). British Journal of Dermatology. 188(Supplement_3). 1 indexed citations
9.
Silverberg, Jonathan I., Hwanhee Hong, Jacob P. Thyssen, et al.. (2023). 393 Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis. British Journal of Dermatology. 188(Supplement_3). 3 indexed citations
10.
Eyerich, Kilian, Melinda Gooderham, Stephen Shumack, et al.. (2023). Real‐world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study. Journal of the European Academy of Dermatology and Venereology. 38(2). 340–353. 26 indexed citations
11.
Guttman‐Yassky, Emma, Jonathan I. Silverberg, Diamant Thaçi, et al.. (2023). Upadacitinib treatment withdrawal and retreatment in patients with moderate‐to‐severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial. Journal of the European Academy of Dermatology and Venereology. 37(12). 2558–2568. 12 indexed citations
12.
Blauvelt, Andrew, Barry Ladizinski, Vimal H. Prajapati, et al.. (2023). Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). Journal of the American Academy of Dermatology. 89(3). 478–485. 23 indexed citations
13.
Silverberg, Jonathan I., Hwanhee Hong, Brian Calimlim, et al.. (2023). Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis. Dermatology and Therapy. 13(10). 2247–2264. 24 indexed citations
14.
Silverberg, Jonathan I., Hwanhee Hong, Jacob P. Thyssen, et al.. (2022). Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis. Dermatology and Therapy. 12(5). 1181–1196. 39 indexed citations
15.
Prens, Errol P., Aída Lugo‐Somolinos, Amy S. Paller, et al.. (2020). Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice. American Journal of Clinical Dermatology. 21(4). 579–590. 16 indexed citations
16.
Guttman‐Yassky, Emma, Diamant Thaçi, Aileen L. Pangan, et al.. (2019). Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 145(3). 877–884. 255 indexed citations breakdown →
17.
Degner, Jacob F., Robert W. Georgantas, Ahmed Nader, et al.. (2019). A Genetic Variant in the BCL2 Gene Associates with Adalimumab Response in Hidradenitis Suppurativa Clinical Trials and Regulates Expression of BCL2. Journal of Investigative Dermatology. 140(3). 574–582.e2. 20 indexed citations
18.
Song, Tao, Ana B. Pavel, Xiangyu Peng, et al.. (2019). 1024 Upadacitinib treatment of atopic dermatitis patients leads to reductions in epidermal hyperplasia and cellular infiltrates. Journal of Investigative Dermatology. 139(5). S177–S177. 3 indexed citations
19.
Menter, Alan, Diamant Thaçi, Kim Papp, et al.. (2015). Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. Journal of the American Academy of Dermatology. 73(3). 410–419.e6. 42 indexed citations
20.
Meneghini, R., Mara Silveira Benfato, Clélia Rejane Antônio Bertoncini, et al.. (1995). Iron homeostasis and oxidative DNA damage. 8(3). 109–113. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna M. Tallman Breakdown of academic impact, for papers by Ga‐Young Ban Breakdown of academic impact, for papers by Martin Raithel Breakdown of academic impact, for papers by William H. Yang Breakdown of academic impact, for papers by Alfonso Oriente Breakdown of academic impact, for papers by M. Lorini Breakdown of academic impact, for papers by R. E. Schopf Breakdown of academic impact, for papers by Ayşen Karaduman Breakdown of academic impact, for papers by Anne Black Breakdown of academic impact, for papers by Charlotte Jonsson
Rankless by CCL
2026